Quick Answer
Arcus Biosciences, Inc. reported Research And Development Expense of $523.00 million for the year ending 2025.
- Arcus Biosciences, Inc. showed an increase of +16.7% in Research And Development Expense from 2024 to 2025.
- This data is from Arcus Biosciences, Inc.'s annual report (Form 10-K), filed with the SEC on February 25, 2026.
- XBRL data for this metric is available from 2016 to 2025 (10 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2017: $5.80 million | Q2 2017: $7.83 million | Q3 2017: $21.44 million | Q1 2018: $11.65 million | Q2 2018: $13.70 million | Q3 2018: $12.86 million | Q1 2019: $15.55 million | Q2 2019: $25.00 million | Q3 2019: $17.24 million | Q1 2020: $23.14 million | Q2 2020: $35.69 million | Q3 2020: $51.80 million | Q1 2021: $66.39 million | Q2 2021: $68.77 million | Q3 2021: $71.25 million | Q1 2022: $61.00 million | Q2 2022: $70.00 million | Q3 2022: $77.00 million | Q1 2023: $81.00 million | Q2 2023: $84.00 million | Q3 2023: $82.00 million | Q1 2024: $109.00 million | Q2 2024: $115.00 million | Q3 2024: $123.00 million | Q1 2025: $122.00 million | Q2 2025: $139.00 million | Q3 2025: $141.00 million.
- Over the full 10 years of available data (2016 to 2025), Arcus Biosciences, Inc.'s Research And Development Expense has grown by 3,570.9%.
- Historical annual values: Fiscal year 2025: $523.00 million | Fiscal year 2024: $448.00 million | Fiscal year 2023: $340.00 million | Fiscal year 2022: $288.00 million | Fiscal year 2021: $257.00 million | Fiscal year 2020: $159.00 million | Fiscal year 2019: $78.48 million | Fiscal year 2018: $49.65 million | Fiscal year 2017: $47.22 million | Fiscal year 2016: $14.25 million.
- Data sourced from SEC EDGAR public filings as of August 8, 2026.
Last verified: